Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy
- 22 January 2018
- journal article
- research article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 129 (1) , 130-135
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation (NRF-2014R1A2A1A11054463)
- Ministry of Science
This publication has 28 references indexed in Scilit:
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in miceJournal of Clinical Investigation, 2014
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis CJournal of Hepatology, 2013
- The Confluence of Stereotactic Ablative Radiotherapy and Tumor ImmunologyJournal of Immunology Research, 2011
- Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular CarcinomaPLOS ONE, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatmentBlood, 2009
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular CarcinomaClinical Cancer Research, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Local recurrence following ‘curative’ surgery for large bowel cancer: I. The overall pictureBritish Journal of Surgery, 1984